Clinical trials: Polycythemia Vera (PV)
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- FREEDOM (NCT03755518)
- Testing
- FEDRATINIB
- Where
- 35 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- Celgene
Polycythemia Vera
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
Study purpose: To compare the efficacy and safety of pegylated interferon α-2b in combination with ruxolitinib versus pegylated interferon α-2b alone for treating hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.
- Trial name
- PV (NCT05870475)
- Testing
- Ruxolitinib, Pegylated interferon α-2b
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Essential Thrombocythemia, Polycythemia Vera
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
This is a phase II open-label study of single agent imetelstat in patients with essential thrombocytopenia or with polycythemia vera who have failed or are intolerant to at least one prior therapy, or who refuse standard therapy.
- Trial name
- ET/PV (NCT01243073)
- Testing
- Imetelstat
- Where
- 12 sites in United States, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- Geron Corporation
Polycythemia Vera (PV), Myelofibrosis (MF)
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and…
- Conditions
- Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis
- Trial name
- NCT07469891
- Testing
- PRT12396
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 100 people
- Sponsor
- Prelude Therapeutics Incorporated
Myelofibrosis
Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
This is an open-label, Phase II Clinical Trial of Aplidin® (plitidepsin) in Patients with Primary Myelofibrosis and post polycythemia vera/essential thrombocythemia (Post-PV/ET) Myelofibrosis.
- Trial name
- NCT01149681
- Testing
- APLIDIN (plitidepsin)
- Where
- 2 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- PharmaMar
Myeloproliferative Neoplasms
HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET
The purpose of this study is to test a new drug called AUY922. AUY922 is not FDA-approved. AUY922 is a new kind of drug that attacks a protein called HSP90.
- Trial name
- NCT01668173
- Testing
- AUY922
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Polycythemia Vera
Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients
Polycythemia Vera (PV) is a disease of bone marrow stem cells that manifests in a drastic increase of red blood cells and frequently also of white blood cells.
- Trial name
- PEN-PV (NCT02523638)
- Testing
- Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
- Where
- 35 sites in Austria, Bulgaria and 6 more
- Volunteers
- 30 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Polycythemia Vera (PV)
A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV
The goal of this clinical trial is to evaluate the efficacy and safety of Gecacitinib in combination with pegylated interferon for the treatment of polycythemia vera (PV).The main question it aims to answer is: Can PV patients…
- Trial name
- NCT07445893
- Testing
- Gecacitinib Hydrochloride Tablets；Pegylated interferon alfa-2b
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Duan Minghui
Polycythemia Vera
LOW-PV Continuation
This multicenter longitudinal observational study focuses on Italian patients with Polycythemia Vera (PV) who were enrolled in the Low-PV RCT and continued receiving Ropeginterferon alfa-2b until the study's conclusion on March…
- Trial name
- CONT-LOW-PV (NCT06752941)
- Where
- 13 sites in Italy
- Volunteers
- 36 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Polycythemia Vera (PV)
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
This is a Phase 2 single arm study to investigate efficacy and safety of P1101 for adult Japanese patients with PV.
- Trial name
- NCT04182100
- Testing
- P1101, Low-dose aspirin, Phlebotomy
- Where
- 8 sites in Japan
- Volunteers
- 29 people
- Sponsor
- PharmaEssentia Japan K.K.
Polycythemia Vera
The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV
The Low-PV study is a multicenter, phase II, randomized trial aimed to assess whether the addition of Pegylated Proline-interferon-alpha-2b to the best therapeutic current strategy available based on phlebotomies and low dose…
- Trial name
- Low-PV (NCT03003325)
- Testing
- AOP2014, Phlebotomies, ASA
- Where
- 23 sites in Italy
- Volunteers
- 127 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Polycythemia Vera
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors
The purpose of this study is to confirm the predictive factors for hydroxyurea (HU) failure (hemoglobin (HGB) <15.5 g/dL (9.62 mmol/L) and red blood cell distribution width (RDW) ≥17%) identified by machine learning in the…
- Trial name
- HU-F-AIM (NCT05853458)
- Testing
- Hydroxyurea
- Where
- 21 sites in Germany
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Polycythemia Vera
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy.
- Trial name
- INTREPID (NCT07429266)
- Testing
- Sapablursen
- Where
- 38 sites in United States, Australia and 7 more
- Volunteers
- 250 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
This extension protocol to the core study CCL09101 allows patients who have tolerated the drug and derived a clinical benefit, to continue to receive treatment beyond the 9 cycles of the core protocol.
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01236638
- Testing
- Momelotinib
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 120 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Polycythemia Vera
AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.
Polycythemia Vera (PV) is a disease of bone marrow stem cells that manifests in a drastic increase of red blood cells and frequently also of white blood cells.
- Trial name
- CONTI-PV (NCT02218047)
- Testing
- Pegylated-Proline-interferon alpha-2b, Best available therapy (BAT)
- Where
- 47 sites in Austria, Bulgaria and 10 more
- Volunteers
- 170 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Primary Myelofibrosis, Polycythemia Vera
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
RO7490677 is an investigational drug that is being developed for possible use in the treatment of myelofibrosis (MF), a disease in which the bone marrow, which is the organ in the body that makes blood cells, is replaced by…
- Conditions
- Primary Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01981850
- Testing
- RO7490677, Ruxolitinib
- Where
- 23 sites in United States, Canada and 6 more
- Volunteers
- 125 people
- Sponsor
- Hoffmann-La Roche
Polycythemia Vera (PV)
Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
This trial adopts an open, randomized, parallel controlled, multicenter clinical trial design planning to enroll patients with polycythemia vera who are resistant/intolerant to hydroxyurea or interferon.
- Trial name
- NCT07232290
- Testing
- Flonoltinib 75mg, Flonoltinib 100mg, Flonoltinib 125mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF)
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor.
- Conditions
- Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
- Trial name
- BOREAS (NCT03662126)
- Testing
- KRT-232, Best Available Therapy (BAT)
- Where
- 191 sites in United States, Argentina and 26 more
- Volunteers
- 385 people
- Sponsor
- Kartos Therapeutics, Inc.
Polycythemia Vera
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
The purpose of the RELIEF study is to compare symptoms in polycythemia vera (PV) subjects treated with ruxolitinib versus subjects treated with hydroxyurea (HU) as measured by the percent of subjects who achieve a clinically…
- Trial name
- NCT01632904
- Testing
- Ruxolitinib, Hydroxyurea (HU)
- Where
- 70 sites in United States, Belgium and 5 more
- Volunteers
- 110 people
- Sponsor
- Incyte Corporation
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
MPN-RC 118 AVID200 in Myelofibrosis
Increased levels of TGF-β1 were detected in serum, plasma and BM and positively correlated with both grade of BMF and extent of leukemic cell infiltration in the marrow.
- Conditions
- Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post ET MF
- Trial name
- NCT03895112
- Testing
- AVID200
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- John Mascarenhas